The legal status of tesamorelin is narrow and routinely misread, because a single FDA-approved use sits next to a large, legally murky gray market. In the United States the record shows one approved indication, off-label prescribing that is lawful within the practice of medicine, off-label promotion that is not, and a much larger volume of material moving through compounding and research-chemical channels that never touches the approved brand at all.
Tesamorelin holds a single FDA approval for HIV-associated lipodystrophy and is prescription-only; off-label prescribing is lawful while marketing unapproved uses is not, and it is unscheduled federally but banned in competitive sport.
Tesamorelin carries one FDA approval, and the record describes it as deliberately specific: reduction of excess visceral abdominal fat in adults with HIV who have lipodystrophy, a fat-redistribution condition tied to long-term HIV and its treatment. The narrowness is the whole point of the regulatory picture, because anything sold for anti-aging, muscle gain, or cosmetic fat loss falls outside what the agency actually evaluated.
The FDA approval covers only reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, so anti-aging, muscle-gain, and cosmetic fat-loss uses are off-label rather than extensions of the approval.
The published record classifies tesamorelin as a prescription-only medicine, meaning lawful dispensing requires the authorization of a licensed prescriber, a physician or, where state law allows, a nurse practitioner or physician assistant. It cannot be sold over the counter or marketed as a dietary supplement, because it is an FDA-approved drug and a peptide hormone analog under drug law rather than the looser supplement framework, and it is delivered as a reconstituted daily subcutaneous injection rather than a shelf product.
Tesamorelin is a prescription-only injectable drug in the United States that cannot lawfully be sold over the counter or marketed as a dietary supplement, so any no-prescription sale is operating outside the pharmacy system or relabeling the product to evade the requirement.
Off-label prescribing and off-label promotion are two different things under United States law, and the distinction is the hinge of tesamorelin's legal picture. A licensed physician may lawfully prescribe an approved drug for a use the FDA never evaluated, because the practice of medicine is regulated by states and the FDA does not police individual prescribing decisions; what is not lawful is a manufacturer, distributor, or clinic marketing the drug for those unapproved uses.
Off-label prescribing by a licensed physician is lawful because the FDA does not regulate individual prescribing, but marketing or advertising tesamorelin for unapproved uses is unlawful promotion that draws FDA and FTC enforcement.
Compounding pharmacies occupy a legally distinct space from drug manufacturers: under sections 503A and 503B of the Food, Drug, and Cosmetic Act they may prepare customized medications, an authority meant to fill genuine clinical gaps rather than recreate mass-market versions of approved drugs. Tesamorelin has been sourced heavily through this channel, and the record shows the FDA scrutinizing it as part of a broader review of peptide compounding, moving a number of peptides into a category flagged for potential safety concerns.
| Criteria | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Prescription basis | Per individual patient prescription | Batches without patient-specific prescriptions |
| Manufacturing standard | Traditional compounding rules | Tighter cGMP-style standards |
| Substance limits | Bound by permissible bulk-substance lists | Bound by permissible bulk-substance lists |
Compounding operates under sections 503A and 503B of the Food, Drug, and Cosmetic Act, and the FDA has flagged a number of peptides for potential safety concerns such as immunogenicity and impurities, narrowing the compounded path for tesamorelin.
The research-chemical or not-for-human-use label is documented as a legal fiction designed to sidestep drug regulation, not a mark of legitimacy or safety. Stamping a vial with "not for human consumption" is an attempt to argue the seller supplies a laboratory reagent rather than a drug, which on paper avoids approval, labeling, and prescription requirements, even though everyone involved understands the material is destined for human injection. That gap between the paper claim and the real use is what makes the channel legally precarious and physically dangerous.
The "not for human use" label is a liability-shifting legal fiction that leaves the buyer with an unapproved, unregulated injectable of unverified identity, purity, and dose and no accountable party standing behind it.
In competitive sport the classification is unambiguous: the World Anti-Doping Agency lists growth hormone releasing factors as a banned class on its Prohibited List, and tesamorelin, a synthetic analog of growth hormone releasing hormone, falls squarely within it alongside related secretagogues. The prohibition applies at all times, in and out of competition, because substances that stimulate the growth hormone axis carry lasting performance and recovery effects that anti-doping rules treat as an ongoing advantage.
The World Anti-Doping Agency prohibits tesamorelin at all times as a growth hormone releasing factor, and a positive test brings an anti-doping rule violation that typically carries a multi-year period of ineligibility and forfeiture of results.
Outside the United States the status is patchy, because drug approval runs jurisdiction by jurisdiction and no single approval travels across borders. Tesamorelin gained its footing through the US FDA for HIV-associated lipodystrophy, and while it has been reviewed or made available in some other markets, in many countries it is not approved or actively marketed at all, leaving no legitimate domestic supply channel and driving a lot of cross-border ordering that collides with import and customs law.
Because drug approval is jurisdiction by jurisdiction, tesamorelin is approved and marketed in some countries and unavailable through legitimate channels in others, and cross-border ordering of the injectable collides with import and customs law and risks seizure.
The record is clear that tesamorelin is not a federally scheduled controlled substance in the United States; it does not appear on the DEA's schedules the way substances with recognized abuse potential do. Being prescription-only and being scheduled are two separate legal statuses, and tesamorelin sits in the first bucket but not the second, so possessing it is not a drug-scheduling offense, though that absence of scheduling does nothing to make gray-market purchase legal or safe.
| Criteria | Prescription-only status | Controlled-substance schedule |
|---|---|---|
| What it requires | A prescriber's authorization to dispense | Criminal-law controls on possession and distribution |
| Governing law | Drug-approval and misbranding law | Controlled Substances Act |
| Tesamorelin | Applies | Does not apply |
| Contrast case | Most approved drugs | Anabolic steroids, placed on Schedule III |
Tesamorelin is prescription-only but not a DEA-scheduled controlled substance, so its legal risk profile is defined by drug-approval and misbranding law rather than by the possession and distribution controls of the Controlled Substances Act.
Educational use only. This article describes what the published scientific and clinical literature reports about Tesamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
